Developer docs
API playgroundTry for free, no card

Search company profiles

Droia Ventures

Full company profile

uuid00043m1

Namestring
Droia Ventures
Legal namestring
Droia SA
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Droia Ventures is a specialist biotech venture capital firm founded in 2015 (per company history), headquartered in Zaventem, Belgium with its primary legal entity Droia SA registered in Luxembourg. The firm invests exclusively in therapeutics for oncology and genetic disease, deploying capital globally into young drug development companies that use novel science and innovative approaches to address previously unsolvable clinical problems. Droia manages over EUR 450 million (USD 550 million) across parallel fund vehicles, including the EUR 220 million Droia Genetic Disease Fund closed in May 2021, and reports 25+ portfolio companies with operations spanning the US, Europe, and Asia.

Droia's core offering combines equity investment with active operational involvement. The firm creates new companies, invests in existing companies, and takes interim roles within portfolio companies to accelerate development from company creation through clinical proof of concept. Droia Labs, a wholly-owned R&D subsidiary operating from Leuven, Belgium, functions as the firm's scientific arm, providing state-of-the-art facilities and in-house scientists to validate novel therapeutic ideas and support portfolio company research. The firm's scientific and operational bench includes Managing Partners Janwillem Naesens (Oncology) and Luc Dochez (Genetic Disease), Partner George Golumbeski (former Celgene EVP of Business Development), and venture partners drawn from Moderna, CRISPR Therapeutics, and Sana Biotechnology.

Revenue is generated through traditional venture capital mechanics: management fees on committed/invested AUM and carried interest on realized exits from successful portfolio companies. The firm has produced multiple liquidity events, including the acquisition of Tusk Therapeutics by Roche and IPOs of Arcus Biosciences (NYSE:RCUS), Aura Biosciences (NASDAQ:AURA), and Cyteir Therapeutics (Nasdaq:CYT). Customer segments comprise early-stage biotech companies seeking specialist investor support beyond capital, and institutional limited partners providing fund commitments. The firm co-invests with tier-one partners including Novartis Venture Fund, Forbion, Polaris Partners, and ARCH Venture Partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersZaventem, Belgium
HQ citystring
Zaventem
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, biotech seed funding, oncology therapeutics investment, genetic disease funding, drug development financing
Industry2 codes
PRIMARYFSANAHAK
Corporate Fintech / Insurtech CVC (Financial-services-led CVC)
SECONDARYBPAGAKAI
Research & Science Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Investment Advice6282
Product category
Biotechnology Venture Capital
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Fund Management
TypeManaged Services
Description

Droia generates revenue through management fees and carried interest from fund returns on successful portfolio company exits.

droiaventures.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Droia Labs
Description

Scientific arm of Droia Ventures that validates novel ideas for young drug development companies

droiaventures.com
Core offering1 text field

Droia Ventures is a specialist early-stage venture capital firm that invests globally in young drug development companies developing therapeutics for oncology and genetic diseases. The firm provides equity capital alongside hands-on operational support from company creation through clinical proof of concept, including taking interim management roles within portfolio companies. Droia Labs, its in-house scientific arm, validates novel therapeutic ideas through state-of-the-art research facilities, while the firm manages over EUR 450 million (USD 550 million) across multiple funds including the EUR 220 million Droia Genetic Disease Fund.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Droia Ventures is a specialist biotech venture capital firm offering investment services exclusively focused on therapeutics for oncology and genetic diseases. The core offering consists of investment capital and hands-on operational support through company creation, development acceleration, and clinical proof of concept. Droia Labs serves as the scientific arm providing state-of-the-art research facilities and expert scientific personnel to validate novel ideas for portfolio companies. The firm manages over EUR 450 million (USD 550 million) across multiple funds, with the recently launched Droia Genetic Disease Fund (EUR 220 million) expanding their genetic disease investment activities alongside their established oncology funds.

Product and service4 records
1Droia Ventures Investment Services
CategoryVenture Capital Investment
Description

Specialist biotech venture capital investment services focused exclusively on therapeutics for oncology and genetic diseases. The firm invests globally in young drug development companies that use novel science and innovative approaches to bring promising therapies to patients, providing hands-on support from company creation through clinical proof of concept.

2Droia Labs
CategoryScientific Research Services
Description

The scientific arm of Droia Ventures that validates novel ideas for young drug development companies. Provides state-of-the-art facilities to deliver cutting-edge science on groundbreaking ideas, with a team of seasoned scientists and entrepreneurs contributing to delivering life-changing medicines to patients.

3Droia Genetic Disease Fund
CategoryVenture Capital Fund
Description

A specialized investment fund of EUR 220 million (USD 265 million) targeting genetic diseases, applying the same specialist investment strategy as Droia's oncology-focused funds. Creates new startups and supports young existing companies financially and scientifically in developing platforms and bringing drug candidates to patients.

4Droia Oncology Ventures
CategoryVenture Capital Fund
Description

Oncology-focused fund vehicle of Droia Ventures that invests in young drug development companies developing novel cancer therapeutics.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Versant Ventures is a healthcare-focused venture firm with operations across the US, Canada, and Europe. It invests across biotech stages and therapeutic areas with a model that combines company creation with traditional venture investing, comparable to Droia's specialist approach.

TypeDirect peer
Description

Atlas Venture is a Boston-based early-stage biotech VC that builds companies from inception and supports them through clinical proof of concept. Its model of company creation and hands-on operational support closely mirrors Droia's investment approach, making it a directly comparable peer.

TypeDirect peer
Description

RA Capital is a Boston-based healthcare-focused investment firm with both public and private strategies, including company creation. Dr. Rez Halse (now at Droia) previously led RA Ventures and the company creation incubator, making RA Capital a directly comparable specialist biotech investor.

TypeEmerging player
Description

5AM Ventures is an early-stage venture firm focused on creating and investing in life sciences companies. While smaller in AUM than the larger specialist VCs, it shares Droia's focus on building biotech companies from novel science with hands-on operational support.

TypeDirect peer
Description

Polaris Partners is a US-based venture firm with a dedicated healthcare/biotech practice. It co-invests in Droia portfolio companies including Volastra, Muna Therapeutics, and Montis Biosciences, making it a directly comparable specialist investor in early-stage therapeutics.

TypeDirect peer
Description

ARCH Venture Partners is a US-based early-stage biotech VC that co-invests in Droia portfolio companies (e.g., Volastra Therapeutics). With a long track record of founding biotech companies from novel science, it is a directly comparable specialist biotech investor.

TypeDirect peer
Description

Forbion is a leading European life sciences venture capital firm managing multiple funds across biotech stages. As a frequent co-investor with Droia (e.g., Protego Biopharma Series B), Forbion is a directly comparable specialist biotech VC with overlapping portfolio companies and a similar European footprint.

TypeDirect peer
Description

Novo Holdings manages the Novo Seeds and Novo Ventures funds, investing in early-stage biotech with a focus on therapeutics and platform technologies. It co-led Muna Therapeutics' Series A with Droia, placing it in the same European biotech specialist peer set.

TypeDirect peer
Description

Novartis Venture Fund is a corporate venture capital arm of Novartis focused on early-stage biotech therapeutics. It co-led Protego Biopharma's $130M Series B with Droia's participation, making it a directly comparable investor in the same oncology and rare disease therapeutic categories.

10EQT Life Sciences (formerly LSP)
TypeDirect peer
Description

EQT Life Sciences is a European healthcare and life sciences specialist investor managing growth and venture funds across biotech and medtech. As a similarly-positioned European biotech VC with comparable AUM scale and therapeutic breadth, it is a directly comparable peer.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment39 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Droia Ventures

Biotechnology Venture Capitaldroiaventures.com

What Droia Ventures does

Droia Ventures is a specialist biotech venture capital firm founded in 2015 (per company history), headquartered in Zaventem, Belgium with its primary legal entity Droia SA registered in Luxembourg. The firm invests exclusively in therapeutics for oncology and genetic disease, deploying capital globally into young drug development companies that use novel science and innovative approaches to address previously unsolvable clinical problems. Droia manages over EUR 450 million (USD 550 million) across parallel fund vehicles, including the EUR 220 million Droia Genetic Disease Fund closed in May 2021, and reports 25+ portfolio companies with operations spanning the US, Europe, and Asia.

Droia's core offering combines equity investment with active operational involvement. The firm creates new companies, invests in existing companies, and takes interim roles within portfolio companies to accelerate development from company creation through clinical proof of concept. Droia Labs, a wholly-owned R&D subsidiary operating from Leuven, Belgium, functions as the firm's scientific arm, providing state-of-the-art facilities and in-house scientists to validate novel therapeutic ideas and support portfolio company research. The firm's scientific and operational bench includes Managing Partners Janwillem Naesens (Oncology) and Luc Dochez (Genetic Disease), Partner George Golumbeski (former Celgene EVP of Business Development), and venture partners drawn from Moderna, CRISPR Therapeutics, and Sana Biotechnology.

Revenue is generated through traditional venture capital mechanics: management fees on committed/invested AUM and carried interest on realized exits from successful portfolio companies. The firm has produced multiple liquidity events, including the acquisition of Tusk Therapeutics by Roche and IPOs of Arcus Biosciences (NYSE:RCUS), Aura Biosciences (NASDAQ:AURA), and Cyteir Therapeutics (Nasdaq:CYT). Customer segments comprise early-stage biotech companies seeking specialist investor support beyond capital, and institutional limited partners providing fund commitments. The firm co-invests with tier-one partners including Novartis Venture Fund, Forbion, Polaris Partners, and ARCH Venture Partners.

Droia Ventures firmographics

Firmographics
Name
Droia Ventures
Legal name
Droia SA
Website
https://droiaventures.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Droia Ventures industry classification

Industry
Product category
Biotechnology Venture Capital
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAHAK
Corporate Fintech / Insurtech CVC (Financial-services-led CVC)
SECONDARYBPAGAKAI
Research & Science Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

Keywords

  • Venture capital investing
  • Biotech seed funding
  • Oncology therapeutics investment
  • Genetic disease funding
  • Drug development financing

Where Droia Ventures is headquartered

Location

Headquarters

HQ city
Zaventem
HQ country
Belgium
HQ region
Europe

Offices3 records

Markets served

Droia Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Fund Management: Droia generates revenue through management fees and carried interest from fund returns on successful portfolio company exits.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Droia Ventures product offering

Product offering

Core offering

Droia Ventures is a specialist early-stage venture capital firm that invests globally in young drug development companies developing therapeutics for oncology and genetic diseases. The firm provides equity capital alongside hands-on operational support from company creation through clinical proof of concept, including taking interim management roles within portfolio companies. Droia Labs, its in-house scientific arm, validates novel therapeutic ideas through state-of-the-art research facilities, while the firm manages over EUR 450 million (USD 550 million) across multiple funds including the EUR 220 million Droia Genetic Disease Fund.

Product overview

Droia Ventures is a specialist biotech venture capital firm offering investment services exclusively focused on therapeutics for oncology and genetic diseases. The core offering consists of investment capital and hands-on operational support through company creation, development acceleration, and clinical proof of concept. Droia Labs serves as the scientific arm providing state-of-the-art research facilities and expert scientific personnel to validate novel ideas for portfolio companies. The firm manages over EUR 450 million (USD 550 million) across multiple funds, with the recently launched Droia Genetic Disease Fund (EUR 220 million) expanding their genetic disease investment activities alongside their established oncology funds.

Differentiator

Problem solved

Functional benefit

Brands

  • Droia Labs: Scientific arm of Droia Ventures that validates novel ideas for young drug development companies

Products and services

  • Droia Ventures Investment Services Specialist biotech venture capital investment services focused exclusively on therapeutics for oncology and genetic diseases. The firm invests globally in young drug development companies that use novel science and innovative approaches to bring promising therapies to patients, providing hands-on support from company creation through clinical proof of concept.
  • Droia Labs The scientific arm of Droia Ventures that validates novel ideas for young drug development companies. Provides state-of-the-art facilities to deliver cutting-edge science on groundbreaking ideas, with a team of seasoned scientists and entrepreneurs contributing to delivering life-changing medicines to patients.
  • Droia Genetic Disease Fund A specialized investment fund of EUR 220 million (USD 265 million) targeting genetic diseases, applying the same specialist investment strategy as Droia's oncology-focused funds. Creates new startups and supports young existing companies financially and scientifically in developing platforms and bringing drug candidates to patients.
  • Droia Oncology Ventures Oncology-focused fund vehicle of Droia Ventures that invests in young drug development companies developing novel cancer therapeutics.

Companies that use Droia Ventures

Customer profile

Segments1 record

Ideal customer profiles1 record

Droia Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Droia Ventures partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Droia Ventures competitors and assessment

Company assessment

Direct peers

  • Versant Ventures: Versant Ventures is a healthcare-focused venture firm with operations across the US, Canada, and Europe. It invests across biotech stages and therapeutic areas with a model that combines company creation with traditional venture investing, comparable to Droia's specialist approach.
  • Atlas Venture: Atlas Venture is a Boston-based early-stage biotech VC that builds companies from inception and supports them through clinical proof of concept. Its model of company creation and hands-on operational support closely mirrors Droia's investment approach, making it a directly comparable peer.
  • RA Capital Management: RA Capital is a Boston-based healthcare-focused investment firm with both public and private strategies, including company creation. Dr. Rez Halse (now at Droia) previously led RA Ventures and the company creation incubator, making RA Capital a directly comparable specialist biotech investor.
  • Polaris Partners: Polaris Partners is a US-based venture firm with a dedicated healthcare/biotech practice. It co-invests in Droia portfolio companies including Volastra, Muna Therapeutics, and Montis Biosciences, making it a directly comparable specialist investor in early-stage therapeutics.
  • ARCH Venture Partners: ARCH Venture Partners is a US-based early-stage biotech VC that co-invests in Droia portfolio companies (e.g., Volastra Therapeutics). With a long track record of founding biotech companies from novel science, it is a directly comparable specialist biotech investor.
  • Forbion: Forbion is a leading European life sciences venture capital firm managing multiple funds across biotech stages. As a frequent co-investor with Droia (e.g., Protego Biopharma Series B), Forbion is a directly comparable specialist biotech VC with overlapping portfolio companies and a similar European footprint.
  • Novo Holdings (Novo Seeds): Novo Holdings manages the Novo Seeds and Novo Ventures funds, investing in early-stage biotech with a focus on therapeutics and platform technologies. It co-led Muna Therapeutics' Series A with Droia, placing it in the same European biotech specialist peer set.
  • Novartis Venture Fund: Novartis Venture Fund is a corporate venture capital arm of Novartis focused on early-stage biotech therapeutics. It co-led Protego Biopharma's $130M Series B with Droia's participation, making it a directly comparable investor in the same oncology and rare disease therapeutic categories.
  • EQT Life Sciences (formerly LSP): EQT Life Sciences is a European healthcare and life sciences specialist investor managing growth and venture funds across biotech and medtech. As a similarly-positioned European biotech VC with comparable AUM scale and therapeutic breadth, it is a directly comparable peer.

Emerging players

  • 5AM Ventures: 5AM Ventures is an early-stage venture firm focused on creating and investing in life sciences companies. While smaller in AUM than the larger specialist VCs, it shares Droia's focus on building biotech companies from novel science with hands-on operational support.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Droia Ventures social profiles

Digital presence

Droia Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Droia Ventures leadership team

Management profile

Number of profiles

Profiles10 records

Droia Ventures subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Droia Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Droia Ventures M&A and investment

M&A and investment

M&A

Investments39 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Droia Ventures

What does Droia Ventures do?

Droia Ventures is a specialist early-stage venture capital firm that invests globally in young drug development companies developing therapeutics for oncology and genetic diseases. The firm provides equity capital alongside hands-on operational support from company creation through clinical proof of concept, including taking interim management roles within portfolio companies. Droia Labs, its in-house scientific arm, validates novel therapeutic ideas through state-of-the-art research facilities, while the firm manages over EUR 450 million (USD 550 million) across multiple funds including the EUR 220 million Droia Genetic Disease Fund.

Is Droia Ventures a public or private company?

Droia Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Droia Ventures founded?

Droia Ventures was founded in 2015. It employs 11 to 50 people.

Where is Droia Ventures based?

Droia Ventures is headquartered in Zaventem, Belgium, in the Europe region.

How does Droia Ventures make money?

One revenue line is on record: fund Management.

Who are Droia Ventures's main competitors?

Direct peers on record are Versant Ventures, Atlas Venture, RA Capital Management, Polaris Partners, ARCH Venture Partners, Forbion, Novo Holdings (Novo Seeds), Novartis Venture Fund and EQT Life Sciences (formerly LSP). 5AM Ventures is listed as an emerging player.

Does Droia Ventures have an API?

No public API is recorded for Droia Ventures.

What industry is Droia Ventures in?

Droia Ventures's product category is Biotechnology Venture Capital. Its primary akta.pro industry code is FSANAHAK, Corporate Fintech / Insurtech CVC (Financial-services-led CVC), with a secondary code of BPAGAKAI, Research & Science Grantmaking Foundations. Its NAICS code is 541714 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LelezardAnaheim Bio lève 40 millions d'euros en série A pour faire avancer l'ANA-1, un traitement contre la maladie de dépôt de pyrophosphate de calcium, jusqu'aux essais cliniquesAnaheim Bio raised a €40 million Series A to advance ANA-1, a small-molecule treatment for calcium pyrophosphate deposition disease (CPPD), into clinical trials. The company expects to enter phase 1 in 2027, with cash reserves through 2028. The funding comes from investors including Droia Ventures and Frazier Life Sciences.FinSMEsAnaheim Bio Raises €40M in Series A FundingAnaheim Bio raised €40M in Series A funding from backers including Droia Ventures, Frazier Life Sciences, and Novartis Venture Fund. The company will use the funds to advance ANA-1, a small molecule for calcium pyrophosphate deposition disease, through IND-enabling studies and into Phase 1.BitlyAnaheim Bio Launches with €40 Million Series A Financing to Advance ANA-1 for Calcium Pyrophosphate Deposition Disease into the ClinicAnaheim Bio, spun out of Alesta Therapeutics, raised €40 million in Series A financing to advance ANA-1, a small molecule for calcium pyrophosphate deposition disease. The company expects clinic entry in 2027, with the financing supporting IND-enabling studies and Phase 1. The lead investors include Droia Ventures, Frazier Life Sciences, and Novartis Venture Fund.pharmaphorumWhich biotechs have raised new VC financing this week?Vaderis Therapeutics raised $152 million in second-round financing to fund its phase 3 trial of engasertib for hereditary haemorrhagic telangiectasia. Aureka Biotechnologies closed a $100 million Series B, Epicrispr raised $90 million, Infinimmune added $75 million, and Boulevard Bio emerged with $65 million.European BiotechnologySwiss biotech Vaderis raises $152M to take first HHT-specific therapy into Phase 3Vaderis Therapeutics raised $152 million in a Series B round to advance engasertib into Phase 3 for hereditary hemorrhagic telangiectasia. The financing, led by Goldman Sachs Alternatives and TCGX, supports the first HHT-specific therapy, with positive proof-of-concept data. The company aims to secure regulatory approval and commercialization.PR NewswireVaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic TelangiectasiaVaderis Therapeutics closed a $152 million Series B financing and initiated the global Phase 3 HEROIC study of engasertib for hereditary hemorrhagic telangiectasia. The study is randomized, double-blind, placebo-controlled, and expected to enroll patients across North America, South America, and Europe. Proceeds will fund operations through regulatory submissions and potential U.S. approval.BioWorldVaderis grabs $152M series B for HHT phase IIIVaderis Therapeutics closed an oversubscribed $152 million series B to advance engasertib (VAD-044) for hereditary hemorrhagic telangiectasia. The round was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors.Tech TimesHHT Patients Get First Phase 3 Drug Trial After 130 Years Without TreatmentVaderis Therapeutics closed a $152 million Series B and launched HEROIC, the first global Phase 3 trial for engasertib in hereditary hemorrhagic telangiectasia. The drug showed a 41% reduction in bleeding duration in a prior proof-of-concept study. The trial aims to secure the first FDA approval for HHT.NewswireVaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic TelangiectasiaVaderis Therapeutics closed a $152 million Series B financing and initiated the global Phase 3 HEROIC study of engasertib for hereditary hemorrhagic telangiectasia. The study is randomized, double-blind, placebo-controlled, and expected to enroll patients across North America, South America, and Europe. Proceeds will fund operations through regulatory submissions and potential U.S. approval.BioSpaceVaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic TelangiectasiaVaderis Therapeutics closed a $152 million Series B financing and initiated the global Phase 3 HEROIC study of engasertib for hereditary hemorrhagic telangiectasia. The study is randomized, double-blind, placebo-controlled, and expected to enroll patients across North America, South America, and Europe. Proceeds will fund operations through regulatory submissions and potential U.S. approval.